Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models

SIMPLE SUMMARY: Lenvatinib has been found to be effective against radioiodine-refractory thyroid cancer. However, compliance with lenvatinib therapy is poor due to cancer progression and adverse effects. To improve the success rate of lenvatinib treatment, we propose a combination of lenvatinib and...

Descripción completa

Detalles Bibliográficos
Autores principales: Enomoto, Keisuke, Hirayama, Shun, Kumashiro, Naoko, Jing, Xuefeng, Kimura, Takahito, Tamagawa, Shunji, Matsuzaki, Ibu, Murata, Shin-Ichi, Hotomi, Muneki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922355/
https://www.ncbi.nlm.nih.gov/pubmed/33670725
http://dx.doi.org/10.3390/cancers13040862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922355/
https://www.ncbi.nlm.nih.gov/pubmed/33670725
http://dx.doi.org/10.3390/cancers13040862

Ejemplares similares